Companies sponsors |
Janssen-Cilag (daratumumab, bortezomib) |
Others |
Department of Health and Social Care |
|
Heath Technology Wales |
|
NHS England |
Patient carer groups |
African Caribbean Leukaemia Trust |
|
Anthony Nolan |
|
Black Health Agency for Equality |
|
Blood Cancer UK |
|
Cancer Black Care |
|
Cancer52 |
|
Helen Rollason Cancer Charity |
|
Independent Cancer Patients Voice |
|
Kevin Karawa Leukaemia Trust |
|
Leukaemia Cancer Society |
|
Leukaemia Care |
|
Leukaemia UK |
|
Macmillan Cancer Support |
|
Maggie’s Centres |
|
Marie Curie |
|
Myeloma UK |
|
South Asian Health Foundation |
|
Specialised Healthcare Alliance |
|
Tenovus Cancer Care |
Professional groups |
Association of Cancer Physicians |
|
British Blood Transfusion Society |
|
British Committee for Standards in Haematology |
|
British Geriatrics Society |
|
British Institute of Radiology |
|
British Oncology Pharmacy Association |
|
British Psychosocial Oncology Society |
|
British Society for Haematology |
|
British Society of Interventional Radiology |
|
British Transplantation Society |
|
Cancer Research UK |
|
NHS Blood and Transplant |
|
Royal College of General Practitioners |
|
Royal College of Nursing |
|
Royal College of Pathologists |
|
Royal College of Physicians |
|
Royal College of Radiologists |
|
Royal Pharmaceutical Society |
|
Royal Society of Medicine |
|
Society and College of Radiographers |
|
UK Clinical Pharmacy Association |
|
UK Myeloma Society |
|
UK Oncology Nursing Society |
Associated public health groups |
Public Health Wales |
|
UK Health Security Agency |
Comparator companies |
Advanz Pharma (lenalidomide) |
|
Amarox (lenalidomide) |
|
Aspire (bortezomib) |
|
Aurobindo Pharma (bortezomib) |
|
Biocon Pharma (lenalidomide) |
|
Biotech Pharma (bortezomib) |
|
Bristol Myers Squibb (lenalidomide, thalidomide) |
|
Dr Reddy’s Laboratories (bortezomib) |
|
Grindeks Kalceks UK (lenalidomide) |
|
MSN laboratories Europe (bortezomib) |
|
Mylan (lenalidomide) |
|
Pfizer (bortezomib) |
|
Piramal Critical Care (lenalidomide) |
|
Ranbaxy UK (bortezomib, lenalidomide) |
|
Sandoz (bortezomib, lenalidomide) |
|
Teva UK (lenalidomide) |
|
Thornton & Ross (bortezomib, lenalidomide) |
|
Tillomed Laboratories (bortezomib) |
|
Zentiva (thalidomide) |
General commentators |
All Wales Therapeutics and Toxicology Centre |
|
Allied Health Professionals Federation |
|
Board of Community Health Councils in Wales |
|
British National Formulary |
|
Care Quality Commission |
|
Department of Health - Northern Ireland |
|
Healthcare Improvement Scotland |
|
Medicines and Healthcare products Regulatory Agency |
|
National Association of Primary Care |
|
National Pharmacy Association |
|
NHS Confederation |
|
NHS Wales Joint Commissioning Committee |
|
Scottish Medicines Consortium |
|
Welsh Government |
Relevant research groups |
Cochrane Haematological Malignancies Group |
|
Genomics England |
|
Institute of Cancer Research |
|
Leukaemia Busters |
|
MRC Clinical Trials Unit |
|
National Institute for Health Research |